(Q36040766)

11 August 2017

1 reference

title

Drug-induced movement disorders in children and adolescents (English)

1 reference

11 August 2017

1 reference

Robert L Rodnitzky

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

Expert Opinion on Drug Safety

11 August 2017

published in

1 reference

11 August 2017

volume

4

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

91-102

1 reference

Psychoactive medication prescribing practices for U.S. children: gaps between research and clinical practice

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Trends in the prescribing of psychotropic medications to preschoolers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Prescribing of psychotropic drugs to children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Use of psychotropic agents in preschool children: associated symptoms, diagnoses, and health care services in a health maintenance organization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Acute dystonia induced by neuroleptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Predictors of acute dystonia in first-episode psychotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

21 January 2018

Citalopram and dystonia

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Ziprasidone-induced oculogyric crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Cocaine-associated dystonic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Acute dystonic reactions to "street Xanax".

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Risperidone-induced neuroleptic malignant syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Neuroleptic Malignant Syndrome and Atypical Antipsychotic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Neuroleptic malignant syndrome: a unique association with a tricyclic antidepressant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Neuroleptic malignant syndrome and methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Case-control study of neuroleptic malignant syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Incidence and risk factors in neuroleptic malignant syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Lack of association in Japanese patients between neuroleptic malignant syndrome and the TaqI A polymorphism of the dopamine D2 receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

The neuroleptic malignant syndrome: a logical approach to the patient with temperature and rigidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Neuroleptic malignant syndrome: two cases without muscle rigidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Neuroleptic malignant syndrome without fever: a report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Drug-induced hyperthermia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Carbamazepine in the treatment of neuroleptic malignant syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Plasmapheresis in neuroleptic malignant syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

RETRACTED: Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992 to 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

21 January 2018

The serotonin syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Selective serotonin reuptake inhibitor-induced serotonin syndrome: review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

A case of serotonin syndrome caused by venlafaxine and lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Sertraline intoxication in a child

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

MDMA (ecstasy) and the rave: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Death following ingestion of MDMA (ecstasy) and moclobemide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Serotonin syndrome and linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Serotonin syndrome complicating migraine pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Sumatriptan contraindications and the serotonin syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

A survey of herbal use in children with attention-deficit-hyperactivity disorder or depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

The serotonin syndrome and its treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Long‐term outcome of quetiapine use for psychosis among parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Worsening of motor features of parkinsonism with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Ziprasidone in Parkinson's disease psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

The epidemiology of drug-induced akathisia: Part I. Acute akathisia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Akathisia: a review and case report following paroxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Clozapine-induced akathisia in children with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Akathisia as a side effect of antipsychotic treatment with quetiapine in a patient with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Akathisia: a comprehensive review and treatment summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Managing antipsychotic-induced acute and chronic akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Intravenous benztropine and propranolol challenges in tardive akathisia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Anticonvulsants-induced chorea: a role for pharmacodynamic drug interaction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Phenytoin-induced choreoathetosis in patients with severe myoclonic epilepsy in infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Movement disorders in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Recognition and differential diagnosis of tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

In Search of Treatment for Tardive Dyskinesia: Review of the Literature*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Treatment of tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Long-term effects of tetrabenazine in hyperkinetic movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Naltrexone treatment of tardive dyskinesia in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

A treatment for tardive dyskinesia and some other extrapyramidal symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Pallidal and thalamic neurostimulation in severe tardive dystonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Risperidone-induced tardive dyskinesia and parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

Vitamin E (α-Tocopherol) in the Treatment of Tardive Dyskinesia: A Statistical Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.1.91

21 January 2018

Identifiers

DOI

10.1517/14740338.4.1.91

1 reference

11 August 2017

1 reference